Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.

Bowen W, Batra L, Pulsifer AR, Yolcu ES, Lawrenz MB, Shirwan H.

Vaccine. 2019 Sep 10;37(38):5708-5716. doi: 10.1016/j.vaccine.2019.07.103. Epub 2019 Aug 12.

PMID:
31416643
2.

Intracellular Assays to Monitor Survival and Growth of Yersinia pestis Within Macrophages.

Pulsifer AR, VanCleave TT, Lawrenz MB.

Methods Mol Biol. 2019;2010:181-196. doi: 10.1007/978-1-4939-9541-7_13.

PMID:
31177439
3.

The Evolution of SlyA/RovA Transcription Factors from Repressors to Countersilencers in Enterobacteriaceae.

Will WR, Brzovic P, Le Trong I, Stenkamp RE, Lawrenz MB, Karlinsey JE, Navarre WW, Main-Hester K, Miller VL, Libby SJ, Fang FC.

MBio. 2019 Mar 5;10(2). pii: e00009-19. doi: 10.1128/mBio.00009-19.

4.

Inflammasome-Independent Leukotriene B4 Production Drives Crystalline Silica-Induced Sterile Inflammation.

Hegde B, Bodduluri SR, Satpathy SR, Alghsham RS, Jala VR, Uriarte SM, Chung DH, Lawrenz MB, Haribabu B.

J Immunol. 2018 May 15;200(10):3556-3567. doi: 10.4049/jimmunol.1701504. Epub 2018 Apr 2.

5.

Yersinia pestis Targets the Host Endosome Recycling Pathway during the Biogenesis of the Yersinia-Containing Vacuole To Avoid Killing by Macrophages.

Connor MG, Pulsifer AR, Chung D, Rouchka EC, Ceresa BK, Lawrenz MB.

MBio. 2018 Feb 20;9(1). pii: e01800-17. doi: 10.1128/mBio.01800-17.

6.

Impact of Gentamicin Concentration and Exposure Time on Intracellular Yersinia pestis.

VanCleave TT, Pulsifer AR, Connor MG, Warawa JM, Lawrenz MB.

Front Cell Infect Microbiol. 2017 Dec 11;7:505. doi: 10.3389/fcimb.2017.00505. eCollection 2017.

7.

Crystal structure of Yersinia pestis virulence factor YfeA reveals two polyspecific metal-binding sites.

Radka CD, DeLucas LJ, Wilson LS, Lawrenz MB, Perry RD, Aller SG.

Acta Crystallogr D Struct Biol. 2017 Jul 1;73(Pt 7):557-572. doi: 10.1107/S2059798317006349. Epub 2017 Jun 30.

8.

Zinc transporters YbtX and ZnuABC are required for the virulence of Yersinia pestis in bubonic and pneumonic plague in mice.

Bobrov AG, Kirillina O, Fosso MY, Fetherston JD, Miller MC, VanCleave TT, Burlison JA, Arnold WK, Lawrenz MB, Garneau-Tsodikova S, Perry RD.

Metallomics. 2017 Jun 21;9(6):757-772. doi: 10.1039/c7mt00126f.

9.

Host FIH-Mediated Asparaginyl Hydroxylation of Translocated Legionella pneumophila Effectors.

Price C, Merchant M, Jones S, Best A, Von Dwingelo J, Lawrenz MB, Alam N, Schueler-Furman O, Kwaik YA.

Front Cell Infect Microbiol. 2017 Mar 6;7:54. doi: 10.3389/fcimb.2017.00054. eCollection 2017.

10.

Novel Synthesis of Kanamycin Conjugated Gold Nanoparticles with Potent Antibacterial Activity.

Payne JN, Waghwani HK, Connor MG, Hamilton W, Tockstein S, Moolani H, Chavda F, Badwaik V, Lawrenz MB, Dakshinamurthy R.

Front Microbiol. 2016 May 2;7:607. doi: 10.3389/fmicb.2016.00607. eCollection 2016.

11.

Yersinia pestis Requires Host Rab1b for Survival in Macrophages.

Connor MG, Pulsifer AR, Price CT, Abu Kwaik Y, Lawrenz MB.

PLoS Pathog. 2015 Oct 23;11(10):e1005241. doi: 10.1371/journal.ppat.1005241. eCollection 2015 Oct.

12.

Nanotechnology's Impact on Medicinal Chemistry.

Hamilton W, Modi T, Waghwani HK, Tockstein S, Payne J, Filani O, Badwaik V, Shah M, Webb C, Lawrenz MB, Dakshinamurthy R.

Mini Rev Med Chem. 2015 May 11. [Epub ahead of print]

PMID:
25963566
13.

Development and evaluation of murine lung-specific disease models for Pseudomonas aeruginosa applicable to therapeutic testing.

Lawrenz MB, Biller AE, Cramer DE, Kraenzle JL, Sotsky JB, Vanover CD, Yoder-Himes DR, Pollard A, Warawa JM.

Pathog Dis. 2015 Jul;73(5). pii: ftv025. doi: 10.1093/femspd/ftv025. Epub 2015 Apr 9.

14.

Intubation-mediated intratracheal (IMIT) instillation: a noninvasive, lung-specific delivery system.

Lawrenz MB, Fodah RA, Gutierrez MG, Warawa J.

J Vis Exp. 2014 Nov 17;(93):e52261. doi: 10.3791/52261.

15.

Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.

Dinc G, Pennington JM, Yolcu ES, Lawrenz MB, Shirwan H.

Vaccine. 2014 Sep 3;32(39):5035-40. doi: 10.1016/j.vaccine.2014.07.015. Epub 2014 Jul 18.

PMID:
25045812
16.

Gold nanoparticles: various methods of synthesis and antibacterial applications.

Shah M, Badwaik V, Kherde Y, Waghwani HK, Modi T, Aguilar ZP, Rodgers H, Hamilton W, Marutharaj T, Webb C, Lawrenz MB, Dakshinamurthy R.

Front Biosci (Landmark Ed). 2014 Jun 1;19:1320-44. Review.

PMID:
24896353
17.

Bioluminescent imaging of bacteria during mouse infection.

Warawa JM, Lawrenz MB.

Methods Mol Biol. 2014;1098:169-81. doi: 10.1007/978-1-62703-718-1_14.

PMID:
24166377
18.

Acquisition of omptin reveals cryptic virulence function of autotransporter YapE in Yersinia pestis.

Lawrenz MB, Pennington J, Miller VL.

Mol Microbiol. 2013 Jul;89(2):276-87. doi: 10.1111/mmi.12273. Epub 2013 Jun 10.

19.

Development of bioluminescent bioreporters for in vitro and in vivo tracking of Yersinia pestis.

Sun Y, Connor MG, Pennington JM, Lawrenz MB.

PLoS One. 2012;7(10):e47123. doi: 10.1371/journal.pone.0047123. Epub 2012 Oct 11.

20.

Expression during host infection and localization of Yersinia pestis autotransporter proteins.

Lenz JD, Lawrenz MB, Cotter DG, Lane MC, Gonzalez RJ, Palacios M, Miller VL.

J Bacteriol. 2011 Nov;193(21):5936-49. doi: 10.1128/JB.05877-11. Epub 2011 Aug 26.

21.

The dependence of the Yersinia pestis capsule on pathogenesis is influenced by the mouse background.

Weening EH, Cathelyn JS, Kaufman G, Lawrenz MB, Price P, Goldman WE, Miller VL.

Infect Immun. 2011 Feb;79(2):644-52. doi: 10.1128/IAI.00981-10. Epub 2010 Nov 29.

22.

Model systems to study plague pathogenesis and develop new therapeutics.

Lawrenz MB.

Front Microbiol. 2010 Nov 4;1:119. doi: 10.3389/fmicb.2010.00119. eCollection 2010.

23.

A novel autotransporter adhesin is required for efficient colonization during bubonic plague.

Lawrenz MB, Lenz JD, Miller VL.

Infect Immun. 2009 Jan;77(1):317-26. doi: 10.1128/IAI.01206-08. Epub 2008 Oct 20.

24.

The Yersinia pestis autotransporter YapC mediates host cell binding, autoaggregation and biofilm formation.

Felek S, Lawrenz MB, Krukonis ES.

Microbiology. 2008 Jun;154(Pt 6):1802-12. doi: 10.1099/mic.0.2007/010918-0.

PMID:
18524935
25.

Comparative analysis of the regulation of rovA from the pathogenic yersiniae.

Lawrenz MB, Miller VL.

J Bacteriol. 2007 Aug;189(16):5963-75. Epub 2007 Jun 15.

26.
27.

Invasin and beyond: regulation of Yersinia virulence by RovA.

Ellison DW, Lawrenz MB, Miller VL.

Trends Microbiol. 2004 Jun;12(6):296-300. Review.

PMID:
15165608
28.

Effect of complement component C3 deficiency on experimental Lyme borreliosis in mice.

Lawrenz MB, Wooten RM, Zachary JF, Drouin SM, Weis JJ, Wetsel RA, Norris SJ.

Infect Immun. 2003 Aug;71(8):4432-40.

29.

A plasmid-encoded nicotinamidase (PncA) is essential for infectivity of Borrelia burgdorferi in a mammalian host.

Purser JE, Lawrenz MB, Caimano MJ, Howell JK, Radolf JD, Norris SJ.

Mol Microbiol. 2003 May;48(3):753-64.

31.

Crystal structure of Lyme disease variable surface antigen VlsE of Borrelia burgdorferi.

Eicken C, Sharma V, Klabunde T, Lawrenz MB, Hardham JM, Norris SJ, Sacchettini JC.

J Biol Chem. 2002 Jun 14;277(24):21691-6. Epub 2002 Mar 28.

32.

Human antibody responses to VlsE antigenic variation protein of Borrelia burgdorferi.

Lawrenz MB, Hardham JM, Owens RT, Nowakowski J, Steere AC, Wormser GP, Norris SJ.

J Clin Microbiol. 1999 Dec;37(12):3997-4004.

Supplemental Content

Loading ...
Support Center